Candriam SCA’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-60,964
| Closed | -$2M | – | 721 |
|
|
2025
Q1 | $2M | Sell |
60,964
-48,363
| -44% | -$1.58M | 0.01% | 495 |
|
|
2024
Q4 | $3.95M | Sell |
109,327
-32,562
| -23% | -$1.18M | 0.02% | 391 |
|
|
2024
Q3 | $4.42M | Hold |
141,889
| – | – | 0.03% | 384 |
|
|
2024
Q2 | $3.8M | Buy |
+141,889
| New | +$3.8M | 0.02% | 383 |
|
|
2020
Q4 | – | Sell |
-20,000
| Closed | -$417K | – | 846 |
|
|
2020
Q3 | $417K | Sell |
20,000
-14,000
| -41% | -$292K | ﹤0.01% | 724 |
|
|
2020
Q2 | $808K | Sell |
34,000
-159,000
| -82% | -$3.78M | 0.01% | 630 |
|
|
2020
Q1 | $4.48M | Hold |
193,000
| – | – | 0.05% | 379 |
|
|
2019
Q4 | $4.58M | Sell |
193,000
-99,000
| -34% | -$2.35M | 0.05% | 387 |
|
|
2019
Q3 | $8.02M | Buy |
292,000
+7,000
| +2% | +$192K | 0.11% | 227 |
|
|
2019
Q2 | $9.39M | Buy |
285,000
+75,000
| +36% | +$2.47M | 0.12% | 200 |
|
|
2019
Q1 | $7.36M | Buy |
210,000
+75,000
| +56% | +$2.63M | 0.09% | 244 |
|
|
2018
Q4 | $4.49M | Buy |
+135,000
| New | +$4.49M | 0.07% | 300 |
|
|
2017
Q4 | – | Sell |
-89,000
| Closed | -$3.56M | – | 775 |
|
|
2017
Q3 | $3.56M | Buy |
89,000
+18,000
| +25% | +$720K | 0.06% | 340 |
|
|
2017
Q2 | $3.06M | Sell |
71,000
-61,000
| -46% | -$2.63M | 0.06% | 379 |
|
|
2017
Q1 | $4.13M | Buy |
132,000
+45,000
| +52% | +$1.41M | 0.08% | 289 |
|
|
2016
Q4 | $2.2M | Buy |
+87,000
| New | +$2.2M | 0.05% | 353 |
|
|
2015
Q1 | – | Sell |
-63,000
| Closed | -$523K | – | 659 |
|
|
2014
Q4 | $523K | Buy |
+63,000
| New | +$523K | 0.01% | 514 |
|